Consolidated Statements of Operations (Unaudited)) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 580,296	$ 1,556,672
General and administrative	3,763,910	481,209
Total operating expenses	4,344,206	2,037,881
Loss from operations	(4,344,206)	(2,037,881)
Other expense:
Interest expense, net	(297,464)	(520,907)
Change in fair value of derivative on debt	(190,841)	(536,345)
Loss on extinguishment / conversion of debt	(257,810)	(27,504)
Total other expense	(746,115)	(1,084,756)
Net loss before non-controlling interests	(5,090,321)	(3,122,637)
Net loss attributable to non-controlling interests	(240,540)	(319,557)
Net loss attributable to Oncotelic Therapeutics, Inc.	$ (4,849,781)	$ (2,803,080)
Basic and diluted net loss per share attributable to common stock	$ (0.01)	$ (0.03)
Basic and diluted weighted average common stock outstanding	377,392,785	94,193,348